Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorobenzene SCHEMBL27930268 | 0.84 | KMT2A (0.43) | CA1CA2L3MBTL1KMT2AMEN1 | |
| SCHEMBL19809912 | 0.84 | L3MBTL1 (0.45) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL196957 | 0.83 | SMN1; SMN2 (0.47) | CA1CA2L3MBTL1KMT2AMEN1 | |
| SCHEMBL6114697 | 0.83 | MEN1 (0.46) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL15000837 | 0.83 | MEN1 (0.46) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL27670053 | 0.81 | CA2 (0.46) | CA1CA2MMP1MMP9MMP13 | |
| SCHEMBL28996978 | 0.81 | ENPP2 (0.46) | CA1CA2PTGS2PTGS1 | |
| SCHEMBL76249 | 0.81 | GAA (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL552333 | 0.81 | GAA (0.57) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1472371 | 0.80 | RECQL (0.50) | CA1CA2L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3276735-B1 | NONAQUEOUS ELECTROLYTE FOR SODIUM SECONDARY BATTERY AND SODIUM SECONDARY BATTERY | SUMITOMO CHEMICAL CO (JP) | 2023-07-12 | — | — | EP | disclosed |
| CN-107431246-B | Nonaqueous electrolyte for sodium secondary battery and sodium secondary battery | 住友化学株式会社 | 2021-03-09 | — | — | CN | disclosed |
| EP-2827433-B1 | SECONDARY BATTERY ELECTROLYTE AND SECONDARY BATTERY USING SAME | ENVISION AESC ENERGY DEVICES LTD (JP) | 2019-09-25 | — | — | EP | disclosed |
| US-20180123170-A1 | NONAQUEOUS ELECTROLYTE FOR SODIUM SECONDARY BATTERY AND SODIUM SECONDARY BATTERY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3276735-A1 | NONAQUEOUS ELECTROLYTE FOR SODIUM SECONDARY CELL, AND SODIUM SECONDARY CELL | Sumitomo Chemical Company, Ltd. (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-8389564-B2 | Proteasome inhibitors | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120270919-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8227503-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| CN-102187511-A | Nonaqueous electrolyte, and nonaqueous electrolyte secondary battery using same | PANASONIC CORP | 2011-09-14 | — | — | CN | disclosed |
| US-20110200886-A1 | NON-AQUEOUS ELECTROLYTE AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | PANASONIC CORPORATION (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20090298906-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| CN-100475803-C | Heterocyclic onium salt | WAKO PURE CHEM IND LTD (JP) | 2009-04-08 | — | — | CN | disclosed |
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| CN-100418947-C | Hybrid onium salts | WAKO PURE CHEM IND LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
| CN-1295211-C | Process for producing aminoalkylsulfonic acid and method of salt exchange for salt thereof | WAKO PURE CHEM IND LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
| CN-1854133-A | Heterocycle-bearing onium salts | WAKO PURE CHEM IND LTD (JP) | 2006-11-01 | — | — | CN | disclosed |
| CN-1678574-A | Process for producing aminoalkylsulfonic acid and method of salt exchange for salt thereof | WAKO PURE CHEM IND LTD (JP) | 2005-10-05 | — | — | CN | disclosed |
| CN-1622943-A | Heterocyclic onium salt | WAKO PURE CHEM IND LTD (JP) | 2005-06-01 | — | — | CN | disclosed |
| CN-1578766-A | Hybrid onium salt | WAKO PURE CHEM IND LTD (JP) | 2005-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270919-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | CA1 3708/4885CA2 4532/4885MMP1 2572/4885 |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | CA1 3075/4885CA2 3033/4885MMP1 3577/4885 |
| US-20090298906-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | CA1 3708/4885CA2 4532/4885MMP1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.